Celldex Therapeutics (NASDAQ:CLDX) Rating Reiterated by HC Wainwright

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $80.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 94.13% from the company’s current price.

Several other analysts have also recently commented on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research report on Friday, March 22nd. Guggenheim raised their price target on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $66.00.

Celldex Therapeutics Stock Performance

Celldex Therapeutics stock opened at $41.21 on Tuesday. Celldex Therapeutics has a one year low of $22.11 and a one year high of $53.18. The company has a 50-day simple moving average of $41.71 and a 200-day simple moving average of $37.03. The firm has a market capitalization of $2.30 billion, a P/E ratio of -14.16 and a beta of 1.60.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.19. Celldex Therapeutics had a negative net margin of 2,054.46% and a negative return on equity of 41.06%. The firm had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $1.20 million. As a group, sell-side analysts forecast that Celldex Therapeutics will post -2.85 earnings per share for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

Several hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP lifted its holdings in shares of Celldex Therapeutics by 19.2% in the fourth quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock valued at $256,860,000 after purchasing an additional 1,044,728 shares in the last quarter. Eventide Asset Management LLC boosted its position in Celldex Therapeutics by 126.9% during the 4th quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock worth $143,966,000 after acquiring an additional 2,030,013 shares during the period. Kynam Capital Management LP grew its stake in Celldex Therapeutics by 23.1% during the 3rd quarter. Kynam Capital Management LP now owns 3,200,000 shares of the biopharmaceutical company’s stock valued at $88,064,000 after acquiring an additional 600,000 shares in the last quarter. Vanguard Group Inc. grew its stake in Celldex Therapeutics by 16.3% during the 4th quarter. Vanguard Group Inc. now owns 3,046,331 shares of the biopharmaceutical company’s stock valued at $120,817,000 after acquiring an additional 427,827 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in shares of Celldex Therapeutics by 105.3% in the 4th quarter. Point72 Asset Management L.P. now owns 2,756,122 shares of the biopharmaceutical company’s stock valued at $109,308,000 after purchasing an additional 1,413,722 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.